The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
Helicos said it will require "significant additional capital" before the end of the year to fund its operations. The company's "current financial resources raise substantial doubt about its ability to continue as a going concern."
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
